EDMONTON, Canada, May 29 /PRNewswire/ -- Isotechnika Inc. announced today that voclosporin is positioned to enter a Phase 1 clinical trial as the drug utilized in the CINATRA(TM) Drug Coated Coronary Stent system developed by the Company's partner, Atrium Medical Corporation. Atrium has received approval from the Belgian Competent Authority to commence the trial.

FREMONT, California, May 29 /PRNewswire/ --

Corsair(R) http://www.corsair.com, a worldwide leader in high performance computer and flash memory products, today announced that it will launch a new 4GB DOMINATOR DDR3 memory kit running at 2000MHz at CompuTex 2008, held June 3-7, 2008 in Taipei. Tested and guaranteed for operation at the lightning fast overclocked speed of 2000MHz, this 4GB DOMINATOR kit provides superior performance for desktop platforms.

SOUTHAMPTON, England, May 29 /PRNewswire/ --

- With Photos

Garmin, global leaders in portable satellite navigation, today announced Mercedes-Benz Accessories will continue its relationship with Garmin by selecting the nüvi 760 as their latest portable after market navigation solution. The nüvi 760 named the 'StreetPilot III' by Mercedes-Benz, is customised with a specially designed mount for the new generation A-Class, B-Class and C-Class cars will be available at dealers across Europe May 2008

NEW YORK, May 29 /PRNewswire/ --

- Provider of Global IPv6 Connectivity Discusses Innovation for Tomorrow's Internet

NTT America, a wholly-owned U.S. subsidiary of NTT Communications Corporation, will engage with key stakeholders including global telecommunications and Internet industry leaders, large enterprises and policy makers at "European IPv6 Day," presented by The Information Society and Media Directorate General of the European Commission on May 30, 2008 at the Robert Schuman room inside the Berlaymont building in Brussels, Belgium. The event will see the launch of the Communication "Advancing the Internet action plan for the deployment of Internet Protocol version 6 (IPv6) in Europe."

COPENHAGEN, Denmark, May 29 /PRNewswire/ -- - Updates on Phase III Studies With Ofatumumab, Zalutumumab and Zanolimumab.

Genmab A/S (OMX: GEN) reports today that the last patient to be included in the planned interim analysis (N=132 patients) in the pivotal Phase III clinical trial of ofatumumab (HuMax-CD20(R)) in refractory chronic lymphocytic leukemia (CLL) has now received the last scheduled treatment.

In order to complete the database and allow for assessment of the responses by an independent committee, the final data will now be collected and analysed with the results expected in early August 2008. Pending a positive outcome, a Biologics License application in this indication is expected to be filed before the end of 2008.

SAN FRANCISCO, May 29 /PRNewswire/ --

- Delivers the most up to date PCI compliance tool to merchants and service providers

AMSTERDAM, Netherlands, May 29 /PRNewswire/ --

- PlayV Ltd to distribute titles in the UK

Today publisher Playlogic Entertainment Inc. (OTC Bulletin Board: PLGC) and publisher/distributor Virgin PLAY announced their joint venture PlayV Ltd.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071119/PLAYLOGICLOGO )

PlayV Ltd, a sales, marketing and distribution business, will bring PC, console and handheld products from both parties to the UK market and also offer flexible pro-active PR, marketing and sales solutions to additional development and publishing partners looking to penetrate the UK retail market with their products.

GHENT, Belgium, May 29 /PRNewswire/ --

- Localisation and Quality Key Criteria for New Applications

Netlog, Europe's leading social networking platform, today announced at the Google I/O conference in San Francisco that it has joined Google's OpenSocial initiative. Starting today, social networking applications developed using the OpenSocial standards can be made available to Netlog's 35 million users across Europe.

DOYLESTOWN, Pennsylvania, May 29 /PRNewswire/ --

- Novel self-expanding intracoronary prosthesis successfully placed in three patients with coronary artery disease

Three patients with established cardiac ischemia recently became the first recipients of the vProtect Luminal Shield, a self-expanding intracoronary prosthesis designed to limit arterial injury that typically occurs when stents are deployed. The Shield also provides robust biocompatible support for the vessel to ensure that the target coronary artery will remain patent after placement.

PARIS, May 29 /PRNewswire/ -- Alcatel-Lucent (Euronext Paris and NYSE: ALU) today announced the availability of its 2007 Corporate Social Responsibility Report. The report underlines Alcatel-Lucent's commitment to corporate social responsibility and presents the main achievements and initiatives undertaken by the company in 2007.

Patricia Russo, CEO of Alcatel-Lucent stated: "Corporate social responsibility has become a business imperative. For Alcatel-Lucent, CSR is not merely a set of policies: it is a key component of the company's business strategy. Going forward we will continue to strengthen CSR within our company to meet the expectations of our shareholders, our customers, our employees, and the communities in which we conduct business."